Maurice C.
Identity and charge heterogeneity
Maurice C. runs cIEF applications on your mAbs, ADCs, and vaccines faster than anything out there. We're talking 10 minutes per sample and method development in a day. You get reliable and reproducible data day in and day out with single-digit CVs, and resolution that trumps HPLC.
He runs cIEF application on your mAbs, ADCs, and vaccines faster than anything out there. We're talking 10 minutes per sample and method development in a day. He'll even give you data on their variants. Already use an iCE system? Method transfer to Maurice is a breeze!
My molecule has complicated charge profiles that are difficult to resolve
Maurice C. affords high-resolution characterization of charge variants by preserving our proprietary imaged capillary isoelectric focusing (icIEF) technology, which has been the go-to method for measuring charge heterogeneity. The whole-column detection eliminates the post-focusing mobilization step needed with traditional cIEF, and can resolve your most challenging molecules including fusion proteins and hydrophobic ADCs.
My current method is not reproducible and error-prone
Maurice C. employs a prequalified, ready-to-use cartridge design which fully automates column conditioning and clean up. No laborious capillary assembly or maintenance is required. The on-board sample mixing feature further enhances the ease-of-use, and reduces operator-dependent variability commonly encountered with other systems.
I have many samples and my schedule is tight
Maurice C. produces pI and charge heterogeneity data in less than 10 minutes. The fast separation time, flexible workflow and high reproducibility makes Maurice C. a true lab workhorse. In one day you can complete your method development, or analyze 48 to 100 samples in one batch. The icing? You can develop platform methods and use them for multiple molecules too.
My sample is limited and they tend to aggregate at high concentration
Maurice C.'s native fluorescence detection for cIEF provides 3-5X higher sensitivity than UV absorption, which means you can now measure sample at concentration as low as 0.7 µg/ml. And because proteins tend to aggregate less at lower concentrations you can reduce or even eliminate urea completely in some of your methods. Baselines are also significantly cleaner and less sensitive to ampholyte interference, giving you more options when optimizing your pH gradient.
I work in a GMP lab and data integrity is key to my compliance requirement
Compass for iCE, the software package Maurice C. uses to acquire, manage and analyze data, has all the tools required for 21 CFR compliance so you'll have no issue analyzing biotherapeutics on Maurice in a regulated environment.
I need to use Empower® 3 Chromatography Data Software
The Maurice Empower® Control Kit lets you control Maurice with Empower® 3 software while maintaining 21 CFR Part 11 compliance. Still want to use Compass for iCE software? Our latest embedded software allows you to use both.
| FEATURE | cIEF SPECIFICATION |
|---|---|
| Minimum Sample Volume | 50 µL |
| Sample Delivery | Vacuum |
| Typical Separation Time | 6–10 min (molecule-dependent) |
| Detection Capability | UV Absorbance at 280 nm Fluorescence: Ex 280 nm, Em 320–450 nm |
| Typical Voltage | Pre-focusing: 1500 V, focusing: 3000 V |
| Sample Injections per Cartridge | 100 |
| Maximum Sample Injections per Batch | 100 guaranteed, 200 maximum |
| pI Range | 2.85–10.45 |
| pI CV | 1% |
| CV for Peaks >10% Composition | ≤5% (Intra-batch), ≤6% (Inter-batch) |
| pI Resolution | 0.05 pI units (for wide range 3–10 ampholytes) |
| Dynamic Range | 2 logs |
| Linearity | >0.995 |
| Sensitivity (LOD) |
0.7 µg/mL (Native fluorescence) 3.0 µg/mL (Absorbance) (Values based on a monoclonal antibody) |
| Sample Tray Options | 96-well plates or 48 vials |
| Dimensions | 44cm H x 42cm W x 61cm D |
| Weight | 46 kg (100 lb) |
Bioprocessing
Cell & Gene Therapy
Protein Charge Heterogeneity
Protein Stability and Formulation Testing
Protein and Antibody Characterization
Post-translational Modification
Biosimilars Characterization
Vaccine Development
